English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

Ad dress for Cor res pon den ce: Şebnem İzmir Güner, Memorial Şişli Hospital, Hematology and Bone Marrow Transplantation Unite, İstanbul, Turkey Phone: +90 212 314 66 66 E-mail: sebnemizmirguner@gmail.com ORCID-ID: orcid.org/0000-0002-6326-9424 Re cei ved: 16.04.2019 Ac cep ted: 22.05.2019 Objective: Patients with recurrent metastatic germ cell tumor (GCT) can be treated with second-line or even third-line regimens; 20-30% of testicular GCT (TGCT) relapse or become refractory after first-line therapy and optimal treatment for this group is not very well defined. Materials and Methods: We presented the analysis of the efficacy of high-dose chemotherapy and peripheral-blood stem-cell transplantation in patients treated between 2016 and 2019. Five patients with five autologous stem-cell transplantations (ASCT) were analyzed retrospectively. All patients were treated with bleomycin, etoposide, cisplatin as first-line therapy and paclitaxel, ifosfamide, cisplatin was given as salvage chemotherapy. Stem–cell collection was performed with granulocyte stimulating factor. ASCT was performed with carboplatin (700 mg/m2) and etoposide (750 mg/ m2). The results were provided as median (min-max). Results: After ASCT, all patients were in complete remission (CR). The follow-up after ASCT was 12 months. At the 12-month follow-up, four patients were still alive and in CR, and only one patient died at 6th month after ASCT due to recurrence. Grade 2/4 toxicities were observed in five patients. Only one patient died due to complications of transplantation. Conclusion: Although the number of the patients in this study was limited, ASCT seemed to be a safe and effective treatment modality in recurrent refractory non-seminomatous TGCT, and treatment-related mortality was very low in this heavily pretreated group.

üroonkoloji bülteni

A Retrospective Study of Patients with Recurrent or Refractory Testicular Germ Cell Tumors Treated with High-dose Chemotherapy and Autologous Peripheral-blood Stem-cell Transplantation Single-center Experience